Malignancy Risks With Biologic Therapies

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The management of rheumatoid arthritis (RA) dramatically changed in 1998 with the introduction of etanercept and infliximab for the treatment of RA and Crohn colitis. Nine biologic agents are currently in use for treating RA. However, speculation has grown that the long-term use of these biopharmaceuticals may alter normal immunosurveillance, thereby contributing to an individual's cancer risk. Whether malignancy is a consequence of rheumatoid inflammation or the therapies used to treat RA has been unclear until recently. This article addresses the growing data on the short- and long-term cancer risks associated with biologic use in RA.

Original languageEnglish (US)
Pages (from-to)761-770
Number of pages10
JournalRheumatic Disease Clinics of North America
Volume38
Issue number4
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Biological Therapy
Rheumatoid Arthritis
Neoplasms
Immunologic Monitoring
Biological Factors
Colitis
Inflammation
Therapeutics

Keywords

  • Biologic agent
  • Cancer
  • Rheumatoid arthritis
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Malignancy Risks With Biologic Therapies. / Cush, John J.; Dao, Kathryn H.

In: Rheumatic Disease Clinics of North America, Vol. 38, No. 4, 01.11.2012, p. 761-770.

Research output: Contribution to journalReview article

@article{d5ccf564f8d942fe9f9cf79386b02f18,
title = "Malignancy Risks With Biologic Therapies",
abstract = "The management of rheumatoid arthritis (RA) dramatically changed in 1998 with the introduction of etanercept and infliximab for the treatment of RA and Crohn colitis. Nine biologic agents are currently in use for treating RA. However, speculation has grown that the long-term use of these biopharmaceuticals may alter normal immunosurveillance, thereby contributing to an individual's cancer risk. Whether malignancy is a consequence of rheumatoid inflammation or the therapies used to treat RA has been unclear until recently. This article addresses the growing data on the short- and long-term cancer risks associated with biologic use in RA.",
keywords = "Biologic agent, Cancer, Rheumatoid arthritis, Tumor necrosis factor",
author = "Cush, {John J.} and Dao, {Kathryn H.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.rdc.2012.09.006",
language = "English (US)",
volume = "38",
pages = "761--770",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Malignancy Risks With Biologic Therapies

AU - Cush, John J.

AU - Dao, Kathryn H.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - The management of rheumatoid arthritis (RA) dramatically changed in 1998 with the introduction of etanercept and infliximab for the treatment of RA and Crohn colitis. Nine biologic agents are currently in use for treating RA. However, speculation has grown that the long-term use of these biopharmaceuticals may alter normal immunosurveillance, thereby contributing to an individual's cancer risk. Whether malignancy is a consequence of rheumatoid inflammation or the therapies used to treat RA has been unclear until recently. This article addresses the growing data on the short- and long-term cancer risks associated with biologic use in RA.

AB - The management of rheumatoid arthritis (RA) dramatically changed in 1998 with the introduction of etanercept and infliximab for the treatment of RA and Crohn colitis. Nine biologic agents are currently in use for treating RA. However, speculation has grown that the long-term use of these biopharmaceuticals may alter normal immunosurveillance, thereby contributing to an individual's cancer risk. Whether malignancy is a consequence of rheumatoid inflammation or the therapies used to treat RA has been unclear until recently. This article addresses the growing data on the short- and long-term cancer risks associated with biologic use in RA.

KW - Biologic agent

KW - Cancer

KW - Rheumatoid arthritis

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=84868345439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868345439&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2012.09.006

DO - 10.1016/j.rdc.2012.09.006

M3 - Review article

C2 - 23137581

AN - SCOPUS:84868345439

VL - 38

SP - 761

EP - 770

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 4

ER -